Cargando…

The Role of Dupilumab in Severe Asthma

Dupilumab is a fully humanized monoclonal antibody, capable of inhibiting intracellular signaling of both interleukin (IL)-4 and IL-13. These are two molecules that, together with other proinflammatory cytokines such as IL-5 and eotaxins, play a pivotal role in orchestrating the airway inflammatory...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ricciardolo, Fabio Luigi Massimo, Bertolini, Francesca, Carriero, Vitina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468984/ https://www.ncbi.nlm.nih.gov/pubmed/34572281 http://dx.doi.org/10.3390/biomedicines9091096

Ejemplares similares

Which Therapy for Non-Type(T)2/T2-Low Asthma
por: Ricciardolo, Fabio L. M., et al.
Publicado: (2021)

Phenotype overlap in the natural history of asthma
por: Ricciardolo, Fabio L.M., et al.
Publicado: (2023)

Characterization of T2-Low and T2-High Asthma Phenotypes in Real-Life
por: Ricciardolo, Fabio Luigi Massimo, et al.
Publicado: (2021)

Clinical Characterization of the Frequent Exacerbator Phenotype in Asthma
por: Sprio, Andrea Elio, et al.
Publicado: (2020)

MicroRNAs as Biomarkers in Corticosteroid-Resistant/Neutrophilic Asthma: Still a Long Way to Go!
por: Ricciardolo, Fabio L. M., et al.
Publicado: (2020)

Critical evaluation of asthma biomarkers in clinical practice
por: Guida, Giuseppe, et al.
Publicado: (2022)

Reliability of Total Serum IgE Levels to Define Type 2 High and Low Asthma Phenotypes
por: Guida, Giuseppe, et al.
Publicado: (2023)

Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience
por: Levra, Stefano, et al.
Publicado: (2022)

Dupilumab and tezepelumab in severe refractory asthma: new opportunities
por: Ragnoli, Beatrice, et al.
Publicado: (2022)

Bone Morphogenic Proteins and Their Antagonists in the Lower Airways of Stable COPD Patients
por: Di Stefano, Antonino, et al.
Publicado: (2023)

Severe pediatric asthma therapy: Dupilumab
por: Ferrante, Giuliana, et al.
Publicado: (2022)

Dupilumab in the management of moderate-to-severe asthma: the data so far
por: Barranco, Pilar, et al.
Publicado: (2017)

Dupilumab in the Treatment of Moderate to Severe Asthma: An Evidence-Based Review
por: Rathinam, Kiran Kumar, et al.
Publicado: (2019)

Dupilumab: a novel treatment for asthma
por: Vatrella, Alessandro, et al.
Publicado: (2014)

Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab
por: van Dijk, Yoni E., et al.
Publicado: (2023)

Successful treatment with dupilumab for mucus plugs in severe asthma
por: Anai, Moriyasu, et al.
Publicado: (2022)

Dupilumab efficacy in adolescents with uncontrolled, moderate‐to‐severe asthma: LIBERTY ASTHMA QUEST
por: Maspero, Jorge F., et al.
Publicado: (2021)

Asthma improvement in patients treated with dupilumab for severe atopic dermatitis
por: Dubini, Marco, et al.
Publicado: (2023)

Pragmatic Markers in the Management of Asthma: A Real-World-Based Approach
por: Ciprandi, Giorgio, et al.
Publicado: (2020)

Differential response to biologics in a patient with severe asthma and ABPA: a role for dupilumab?
por: Mümmler, Carlo, et al.
Publicado: (2020)

Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13
por: Pelaia, Corrado, et al.
Publicado: (2022)

Decreased humoral immune response in the bronchi of rapid decliners with chronic obstructive pulmonary disease
por: Di Stefano, Antonino, et al.
Publicado: (2022)

Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
por: Castro, Mario, et al.
Publicado: (2020)

Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis
por: Pelaia, Corrado, et al.
Publicado: (2021)

Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma
por: Corren, Jonathan, et al.
Publicado: (2021)

Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study
por: Numata, Takanori, et al.
Publicado: (2022)

Dupilumab in a patient with severe asthma and glucocorticoid hypersensitivity: a case report
por: Handa, Hiroshi, et al.
Publicado: (2023)

Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid dose
por: Domingo, Christian, et al.
Publicado: (2023)

Updated Evaluation of Dupilumab in the Treatment of Asthma: Patient Selection and Reported Outcomes
por: Brooks, G Daniel
Publicado: (2020)

Effect of Dupilumab in Korean Patients With Uncontrolled Moderate-to-Severe Asthma: A LIBERTY ASTHMA QUEST Sub-analysis
por: Rhee, Chin Kook, et al.
Publicado: (2022)

Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma
por: Prætorius, Katrine, et al.
Publicado: (2021)

Severe Asthma Where Eosinophilic Granulomatosis with Polyangiitis Became Apparent after the Discontinuation of Dupilumab
por: Ikeda, Miki, et al.
Publicado: (2021)

Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate‐to‐severe type 2 asthma
por: Papi, Alberto, et al.
Publicado: (2022)

Dupilumab for the treatment of severe photodermatitis
por: Smith, Mary Patricia, et al.
Publicado: (2019)

Severe atopic dermatitis and dupilumab
por: Bernardo, Wanderley, et al.
Publicado: (2023)

Severe refractory asthma: current treatment options and ongoing research
por: Menzella, Francesco, et al.
Publicado: (2018)

Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program
por: Campisi, Raffaele, et al.
Publicado: (2021)

Real‐world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta‐analysis
por: Charles, David, et al.
Publicado: (2022)

Dupilumab efficacy and safety in patients with moderate to severe asthma: A systematic review and meta-analysis
por: Zaazouee, Mohamed Sayed, et al.
Publicado: (2022)

Innovative treatments for severe refractory asthma: how to choose the right option for the right patient?
por: Menzella, Francesco, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9sj0c3avv1ve8s9le0mm2lb7so